Centessa Pharmaceuticals plc (CNTA)
NASDAQ: CNTA · Real-Time Price · USD
17.16
-0.39 (-2.22%)
Dec 20, 2024, 4:00 PM EST - Market closed
Centessa Pharmaceuticals Stock Forecast
Stock Price Forecast
The 7 analysts with 12-month price forecasts for CNTA stock have an average target of 23.71, with a low estimate of 11 and a high estimate of 35. The average target predicts an increase of 38.17% from the current stock price of 17.16.
Analyst Consensus: Strong Buy
* Price targets were last updated on Nov 15, 2024.
Analyst Ratings
The average analyst rating for CNTA stock from 7 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jul '24 | Aug '24 | Sep '24 | Oct '24 | Nov '24 | Dec '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 3 | 3 | 3 | 3 |
| Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Hold | 2 | 2 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 7 | 7 | 7 | 7 | 7 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Guggenheim | Guggenheim | Strong Buy Maintains $24 → $28 | Strong Buy | Maintains | $24 → $28 | +63.17% | Nov 15, 2024 |
| Morgan Stanley | Morgan Stanley | Hold → Buy Upgrades $11 → $26 | Hold → Buy | Upgrades | $11 → $26 | +51.52% | Sep 19, 2024 |
| B. Riley Securities | B. Riley Securities | Strong Buy Initiates $33 | Strong Buy | Initiates | $33 | +92.31% | Sep 19, 2024 |
| BMO Capital | BMO Capital | Buy Maintains $20 → $35 | Buy | Maintains | $20 → $35 | +103.96% | Sep 16, 2024 |
| Guggenheim | Guggenheim | Strong Buy Maintains $20 → $24 | Strong Buy | Maintains | $20 → $24 | +39.86% | Sep 11, 2024 |
Financial Forecast
Revenue This Year
n/a
from 6.85M
Revenue Next Year
n/a
EPS This Year
-1.57
from -1.57
EPS Next Year
-1.57
from -1.57
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | n/a | n/a | 30.5M | |||
| Avg | n/a | n/a | 9.8M | |||
| Low | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | - | - | - | |||
| Avg | - | - | - | |||
| Low | - | - | - |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|
| High | -1.54 | -1.14 | -1.06 | |
| Avg | -1.57 | -1.57 | -1.74 | |
| Low | -1.60 | -1.73 | -1.98 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|
| High | - | - | - | |
| Avg | - | - | - | |
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.